Covidien Hernia Mesh (No. II)
The Covidien Hernia Mesh (No. II) litigation was centralized before Judge Patti B. Saris in the District of Massachusetts in June 2022, consolidating claims that Covidien-manufactured hernia mesh products caused chronic pain, infection, adhesion, bowel obstruction, or mesh migration, often requiring revision surgery. The "No. II" designation reflects that this is a distinct, later-formed docket addressing Covidien-specific hernia mesh claims, separate from earlier hernia mesh MDLs involving other manufacturers.
With 2,453 of 2,459 total filed actions still pending, this docket shows an unusually high pending rate for its size — essentially the entire filed population remains active, signaling a docket still in a growth and formation phase rather than one that has begun meaningful claim resolution. What will shape duration and resolution risk going forward includes how quickly the court establishes a bellwether selection process, how the substantial body of general-causation evidence developed in other hernia-mesh MDLs (involving different manufacturers and products) does or does not transfer to claims specific to Covidien's mesh products, and how fast the docket's filing population stabilizes as awareness of the litigation matures.
Hernia mesh litigation as a device category has a well-developed track record across multiple manufacturer-specific MDLs, which gives observers useful comparative context for how this kind of docket typically progresses from formation through bellwether trials to eventual settlement frameworks — even though this specific Covidien docket must still develop its own causation and bellwether record independent of those precedents. Criterica Intelligence's platform tracks both the docket-specific development and the broader device-category pattern across every active MDL, providing a calibrated, comparative read on where a docket like this sits in its lifecycle. A companion capital brief on this docket is available through Criterica Capital.
It indicates this is a separate, later-formed docket specific to Covidien hernia mesh products, distinct from earlier hernia mesh MDLs involving other manufacturers, even though the underlying device category and injury theories overlap.
With 2,453 of 2,459 total filings still pending, the docket is still in a growth and formation phase — very little of the original filing population has resolved, unlike a docket further along its lifecycle.
It provides useful comparative context on how hernia mesh litigation typically progresses, but this Covidien-specific docket must still build its own general-causation and bellwether record independent of outcomes in other manufacturers' dockets.
How quickly the court establishes a bellwether selection process and how the filing population stabilizes as awareness of the litigation matures, since no bellwether trial has yet occurred in this specific proceeding.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.